{"entity":{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","aka":[],"tldr":"Paper by Jan A. Burger indexed on Europe PMC as PubMed record 25700432, in Blood (2015), one of the most cited records naming an author with this name at MD Anderson Cancer Center.","summary":"Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period. We report on median 3-year follow-up of 132 patients with symptomatic treatment-naïve and relapsed/refractory CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions. Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections. Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better. Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.\n\nIndexed on Europe PMC as PubMed record 25700432 (DOI 10.1182/blood-2014-10-606038). Its author list gives \"Burger JA\" with the affiliation \"The University of Texas MD Anderson Cancer Center, Houston, TX; and\", which names MD Anderson Cancer Center; that is how the record was matched to Jan A. Burger, and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Blood 2015","url":"https://doi.org/10.1182/blood-2014-10-606038"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/25700432/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/25700432"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jan-burger"],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"journal":"Blood","year":2015,"doi":"10.1182/blood-2014-10-606038","pmid":"25700432","authors":"Byrd JC, Furman RR, Coutre SE, et al.","paperType":"observational","findings":[],"whatItMeans":"One of the most cited papers Europe PMC returns for Jan A. Burger at MD Anderson Cancer Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched to the person by surname, initials and an affiliation string naming the institution on the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","Two authors sharing a surname, initials and institution cannot be told apart by this method; the person's profile links are the place to confirm authorship."]},"route":"/key-papers/paper-jan-burger-blood-2015/","neighbours":{"person":[{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}